EP 230: From short reads to long reads in clinical genomics with Anna Lindstrand of Karolinska

Value of the Information & Strength of the Argument

The podcast provides valuable insights into the practical implementation of genomic technologies in a clinical setting, based on the extensive experience of a leading expert. The argumentation is solid, grounded in real-world data from the Karolinska’s large-scale sequencing program and recent studies. Lindstrand offers a balanced view, acknowledging the benefits of long-read sequencing while also addressing the challenges of integration and the need for evidence-based implementation. The discussion on the shift toward precision therapeutics and the need for new actionability criteria is particularly thought-provoking, highlighting a paradigm change in clinical genetics.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, as the discussion is based on peer-reviewed studies and national initiatives. The sources cited in the description are relevant and credible, including a study on long-read sequencing and a paper on moving beyond monogenic disease. The title accurately reflects the content, focusing on the transition from short-read to long-read sequencing in clinical genomics. The podcast maintains a professional and evidence-based tone, with no obvious biases or unsupported claims.

The title accurately reflects the content, focusing on the transition from short-read to long-read sequencing in clinical genomics, as discussed with Anna Lindstrand.

8/10

The podcast features a leading clinical geneticist discussing evidence-based practices and recent studies, with references to published research. The information is expert opinion grounded in clinical experience and national initiatives, but not a systematic review or original study.

• 00:00Intro to The Genetics Podcast
• 01:00Welcome to Anna
• 01:34Choosing between whole genome, exome, panels, and long-read sequencing in clinical practice
• 04:21Evaluating long-read sequencing in the clinic
• 07:02What long-read sequencing adds to diagnostic yield
• 09:58The role of RNA sequencing, proteomics, and methylation profiling as complementary tools in clinical genomics
• 14:00Building a coordinated national infrastructure for clinical genomics and rare disease research in Sweden
• 19:27The shift toward precision therapeutics and new standards for clinical actionability
• 24:46Using national genomic data and registries to make Sweden trial-ready for precision therapies
• 28:44Moving beyond monogenic models to capture polygenic and borderline signals in clinical genomics
• 32:47Genomics for prevention including adult screening and pharmacogenomics
• 38:44Research priorities for the next phase of genomic medicine and structural variant discovery
• 41:12Closing remarks

• Long-read sequencing study — Referenced as the study on long-read sequencing in clinical diagnostics.
• Moving beyond monogenic disease paper — Referenced in the discussion about polygenic and borderline signals in clinical genomics.
• Genomic Medicine Sweden overview — Provided as a resource for more information about Genomic Medicine Sweden.

• Long-read sequencing study — Supports the discussion on the added value of long-read sequencing in clinical diagnostics.
• Moving beyond monogenic disease paper — Aligns with the discussion on polygenic and borderline signals in clinical genomics.